Format

Send to

Choose Destination
Nat Rev Immunol. 2010 May;10(5):317-27. doi: 10.1038/nri2744.

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

Author information

1
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC 20057, USA. weinerl@georgetown.edu

Abstract

Antibodies are important therapeutic agents for cancer. Recently, it has become clear that antibodies possess several clinically relevant mechanisms of action. Many clinically useful antibodies can manipulate tumour-related signalling. In addition, antibodies exhibit various immunomodulatory properties and, by directly activating or inhibiting molecules of the immune system, antibodies can promote the induction of antitumour immune responses. These immunomodulatory properties can form the basis for new cancer treatment strategies.

PMID:
20414205
PMCID:
PMC3508064
DOI:
10.1038/nri2744
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center